Rani Therapeutics Holdings Inc (RANI)
$0.87
$0.01
(1.54%)
As on 04-Sep-2026 18:41EDT
Market cap
$122 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.3
-
Face value
--
-
Shares outstanding
115,424,960
5 Years Aggregate
CFO
$-171.22 Mln
EBITDA
$-220.96 Mln
Net Profit
$-193.70 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rani Therapeutics Holdings Inc (RANI)
| -35.9 | 8.0 | -1.1 | 78.3 | -38.9 | -46.5 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Rani Therapeutics Holdings Inc (RANI)
| -1.5 | -58.4 | -43.7 | -63.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rani Therapeutics Holdings Inc (RANI)
|
0.9 | 121.6 | 4.9 | -30.1 | -488.9 | -77.2 | -- | 2.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Rani Therapeutics Holdings Inc (RANI)
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful... injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. Read more
-
Executive Chairman
Mr. Mir A. Imran
-
Executive Chairman
Mr. Mir A. Imran
-
Headquarters
San Jose, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Rani Therapeutics Holdings Inc (RANI)
What is the current share price of Rani Therapeutics Holdings Inc (RANI) Today?
The share price of Rani Therapeutics Holdings Inc (RANI) is $0.87 (NASDAQ) as of 04-Sep-2026 18:41 EDT. Rani Therapeutics Holdings Inc (RANI) has given a return of -38.93% in the last 3 years.
What is the current PB & PE ratio of Rani Therapeutics Holdings Inc (RANI)?
Since, TTM earnings of Rani Therapeutics Holdings Inc (RANI) is negative, P/E ratio is not available.
The P/B ratio of Rani Therapeutics Holdings Inc (RANI) is 2.54 times as on 04-Sep-2026, a 52 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.69 |
6.02 |
2024 |
-1.49 |
22.46 |
2023 |
-2.53 |
6.68 |
2022 |
-4.80 |
3.99 |
2021 |
-38.15 |
6.70 |
What is the 52 Week High and Low of Rani Therapeutics Holdings Inc (RANI)?
The 52-week high and low of Rani Therapeutics Holdings Inc (RANI) are Rs 3.87 and Rs 0.45 as of 08-Sep-2026.
What is the market cap of Rani Therapeutics Holdings Inc (RANI)?
Rani Therapeutics Holdings Inc (RANI) has a market capitalisation of $ 122 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Rani Therapeutics Holdings Inc (RANI)?
Before investing in Rani Therapeutics Holdings Inc (RANI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.